New MAVENCLAD(R) Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression

Source :: Business Wire India (Delhi-NCR, India). February 25, 2022
Publication Year :: 2022
Abstract: Germany, Feb. 25 -- New real-world data show MAVENCLAD(R) (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate [...]

Subjects :: Merck & Company Inc.
High technology industry
Multiple sclerosis -- Development and progression -- Care and treatment
Pharmaceutical industry
Business, international
Mavenclad (Medication)

Tools